Research ExplorerPublicationsBiomarker response and therapy prediction in renal denervati...

Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach

Standard

Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach. / Neumann, Johannes Tobias; Schwerg, Marius; Dörr, Oliver; Mortensen, Kai; Franzen, Klaas; Zeller, Tanja; Ojeda, Francisco; Blankenberg, Stefan; Hamm, Christian; Nef, Holger; Stangl, Verena; Möckel, Martin; Sydow, Karsten.

In: BIOMARKERS, Vol. 22, No. 3-4, 07.05.2016, p. 225-231.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Neumann, JT, Schwerg, M, Dörr, O, Mortensen, K, Franzen, K, Zeller, T, Ojeda, F, Blankenberg, S, Hamm, C, Nef, H, Stangl, V, Möckel, M & Sydow, K 2016, 'Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach', BIOMARKERS, vol. 22, no. 3-4, pp. 225-231. https://doi.org/10.3109/1354750X.2016.1172112

APA

Neumann, J. T., Schwerg, M., Dörr, O., Mortensen, K., Franzen, K., Zeller, T., Ojeda, F., Blankenberg, S., Hamm, C., Nef, H., Stangl, V., Möckel, M., & Sydow, K. (2016). Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach. BIOMARKERS, 22(3-4), 225-231. https://doi.org/10.3109/1354750X.2016.1172112

Vancouver

Neumann JT, Schwerg M, Dörr O, Mortensen K, Franzen K, Zeller T et al. Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach. BIOMARKERS. 2016 May 7;22(3-4):225-231. https://doi.org/10.3109/1354750X.2016.1172112

Bibtex

@article{1d475c7a337440a18c2a69e06c0dd6d3,
title = "Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach",
abstract = "BACKGROUND: Renal denervation has been proposed as a therapeutic option in patients with resistant hypertension. Circulating blood borne biomarkers might be helpful to identify individuals responding to RDN therapy. MR-proADM is a strong prognostic marker in patients with cardiovascular disease. The aim of this multicenter study was to evaluate the effect of RDN on MR-proADM concentrations.METHODS AND RESULTS: We measured MR-proADM, BNP, and MR-proANP in 110 patients before and after RDN in a multicenter setting. All patients were followed up after 1 and 6 months by office and ambulatory blood pressure (BP) measurements. The mean office BP decreased from 165/89 to 152/87 mmHg 6 months after RDN (systolic: p < 0.001; diastolic: ns), the responder-rate was 74%. Intriguingly MR-proADM concentrations increased from 0.66 to 0.69 nmol/L (p < 0.001) and were significantly associated with reduction of systolic office BP after 6 months in multivariate analyses (coefficient -0.0018, p < 0.001). In therapy-responders MR-proADM concentrations showed a significantly higher increase over time (coefficient 0.0105, p < 0.05), as compared to non-responders. There were no significant differences in BP change for individuals with low and high baseline MR-proADM (BP-Delta low MR-proADM -23/-4 mmHg vs. high MR-proADM -24/-5 mmHg). The natriuretic biomarkers BNP and MR-proANP did not change significantly after 6 months. Biomarkers at baseline were not able to predict for therapy-responder.CONCLUSION: In patients undergoing RDN, baseline measurements of various biomarkers had no prognostic use for therapy success in this short time follow-up period in a multicenter approach. Intriguingly, MR-proADM showed a significant association with BP reduction after 6 months.",
keywords = "Adrenomedullin/physiology, Aged, Biomarkers/blood, Blood Pressure, Denervation, Female, Follow-Up Studies, Humans, Hypertension/therapy, Kidney/innervation, Male, Middle Aged, Natriuretic Peptide, Brain/blood, Prognosis, Protein Precursors/physiology, Time Factors, Treatment Outcome",
author = "Neumann, {Johannes Tobias} and Marius Schwerg and Oliver D{\"o}rr and Kai Mortensen and Klaas Franzen and Tanja Zeller and Francisco Ojeda and Stefan Blankenberg and Christian Hamm and Holger Nef and Verena Stangl and Martin M{\"o}ckel and Karsten Sydow",
year = "2016",
month = may,
day = "7",
doi = "10.3109/1354750X.2016.1172112",
language = "English",
volume = "22",
pages = "225--231",
journal = "BIOMARKERS",
issn = "1354-750X",
publisher = "informa healthcare",
number = "3-4",

}

RIS

TY - JOUR

T1 - Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach

AU - Neumann, Johannes Tobias

AU - Schwerg, Marius

AU - Dörr, Oliver

AU - Mortensen, Kai

AU - Franzen, Klaas

AU - Zeller, Tanja

AU - Ojeda, Francisco

AU - Blankenberg, Stefan

AU - Hamm, Christian

AU - Nef, Holger

AU - Stangl, Verena

AU - Möckel, Martin

AU - Sydow, Karsten

PY - 2016/5/7

Y1 - 2016/5/7

N2 - BACKGROUND: Renal denervation has been proposed as a therapeutic option in patients with resistant hypertension. Circulating blood borne biomarkers might be helpful to identify individuals responding to RDN therapy. MR-proADM is a strong prognostic marker in patients with cardiovascular disease. The aim of this multicenter study was to evaluate the effect of RDN on MR-proADM concentrations.METHODS AND RESULTS: We measured MR-proADM, BNP, and MR-proANP in 110 patients before and after RDN in a multicenter setting. All patients were followed up after 1 and 6 months by office and ambulatory blood pressure (BP) measurements. The mean office BP decreased from 165/89 to 152/87 mmHg 6 months after RDN (systolic: p < 0.001; diastolic: ns), the responder-rate was 74%. Intriguingly MR-proADM concentrations increased from 0.66 to 0.69 nmol/L (p < 0.001) and were significantly associated with reduction of systolic office BP after 6 months in multivariate analyses (coefficient -0.0018, p < 0.001). In therapy-responders MR-proADM concentrations showed a significantly higher increase over time (coefficient 0.0105, p < 0.05), as compared to non-responders. There were no significant differences in BP change for individuals with low and high baseline MR-proADM (BP-Delta low MR-proADM -23/-4 mmHg vs. high MR-proADM -24/-5 mmHg). The natriuretic biomarkers BNP and MR-proANP did not change significantly after 6 months. Biomarkers at baseline were not able to predict for therapy-responder.CONCLUSION: In patients undergoing RDN, baseline measurements of various biomarkers had no prognostic use for therapy success in this short time follow-up period in a multicenter approach. Intriguingly, MR-proADM showed a significant association with BP reduction after 6 months.

AB - BACKGROUND: Renal denervation has been proposed as a therapeutic option in patients with resistant hypertension. Circulating blood borne biomarkers might be helpful to identify individuals responding to RDN therapy. MR-proADM is a strong prognostic marker in patients with cardiovascular disease. The aim of this multicenter study was to evaluate the effect of RDN on MR-proADM concentrations.METHODS AND RESULTS: We measured MR-proADM, BNP, and MR-proANP in 110 patients before and after RDN in a multicenter setting. All patients were followed up after 1 and 6 months by office and ambulatory blood pressure (BP) measurements. The mean office BP decreased from 165/89 to 152/87 mmHg 6 months after RDN (systolic: p < 0.001; diastolic: ns), the responder-rate was 74%. Intriguingly MR-proADM concentrations increased from 0.66 to 0.69 nmol/L (p < 0.001) and were significantly associated with reduction of systolic office BP after 6 months in multivariate analyses (coefficient -0.0018, p < 0.001). In therapy-responders MR-proADM concentrations showed a significantly higher increase over time (coefficient 0.0105, p < 0.05), as compared to non-responders. There were no significant differences in BP change for individuals with low and high baseline MR-proADM (BP-Delta low MR-proADM -23/-4 mmHg vs. high MR-proADM -24/-5 mmHg). The natriuretic biomarkers BNP and MR-proANP did not change significantly after 6 months. Biomarkers at baseline were not able to predict for therapy-responder.CONCLUSION: In patients undergoing RDN, baseline measurements of various biomarkers had no prognostic use for therapy success in this short time follow-up period in a multicenter approach. Intriguingly, MR-proADM showed a significant association with BP reduction after 6 months.

KW - Adrenomedullin/physiology

KW - Aged

KW - Biomarkers/blood

KW - Blood Pressure

KW - Denervation

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hypertension/therapy

KW - Kidney/innervation

KW - Male

KW - Middle Aged

KW - Natriuretic Peptide, Brain/blood

KW - Prognosis

KW - Protein Precursors/physiology

KW - Time Factors

KW - Treatment Outcome

U2 - 10.3109/1354750X.2016.1172112

DO - 10.3109/1354750X.2016.1172112

M3 - SCORING: Journal article

C2 - 27153479

VL - 22

SP - 225

EP - 231

JO - BIOMARKERS

JF - BIOMARKERS

SN - 1354-750X

IS - 3-4

ER -